Company Overview and News
CombiMatrix Corp. (NASDAQ:CBMX) has 17 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,611,160 shares. Largest shareholders include Acuta Capital Partners, Llc, Frigate Ventures LP, MMCAP International Inc. SPC, Renaissance Technologies LLC, Deutsche Bank Ag\, Stonepine Capital Management, LLC, Bridgeway Capital Management Inc, Asymmetry Capital Management, L.
Stonepine Capital Management, LLC has disclosed 22 total holdings in their latest SEC filings. Most recent portfolio value is calculated to be $ 167,888,000 USD. Actual Assets Under Management (AUM) is this value plus cash (which is not disclosed). Stonepine Capital Management, LLC's top holdings are Viveve Medical, Inc. (OTC:VIVMF) , Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) , Pacira Pharmaceuticals, Inc.
The deal is very small with a total value of roughly $33MM, which will lead to very little institutional attention.
* Combimatrix Corp says approximately 1.79 million of common shares voting in meeting voted in favor of approval & adoption of all-stock merger agreement Source text for Eikon: Further company coverage:
SAN FRANCISCO, July 31, 2017 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced two acquisitions to establish a leading position in family health genetic information services. Invitae has entered into a definitive agreement to acquire privately held Good Start Genetics, a molecular diagnostics company focused on preimplantation and carrier screening for inherited disorders.
-- Good Start Genetics Provides Best-in-Class Carrier and NGS Preimplantation Screening to Leading IVF Centers -- -- CombiMatrix Trusted for Advanced DNA Diagnostics by Reproductive Health and Pediatric Specialists -- -- Invitae to Host Webcast for Investors on August 1 at 8 am ET / 5 am PT --
According to a new market research report "Preimplantation Genetic Testing Market by Type (Genetic Diagnosis/Genetic Screening), Technology (NGS, PCR, FISH, CGH, SNP), Products & Services, Application (Aneuploidy, Translocations), End User (Fertility Clinics, Research) - Forecast to 2022", published by MarketsandMarkets™, the Global Preimplantation Genetic Testing Market is projected to reach USD 541.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2016 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO .
LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these presents, that the undersigned hereby makes, constitutes and appoints Scott R. Burell of CombiMatrix Corporation, Parker Schweich of Stradling Yocca Carlson & Rauth, P.C. and Lisa Ann Latham of Stradling Yocca Carlson & Rauth, P.C., and each of them, as the undersigned's true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the under
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) February 27, 2017 CombiMatrix Corporation (Exact name of registrant as specified in its charter) Delaware 001-33523 47-0899439 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
CombiMatrix Corporation Reports 2016 Fourth Quarter and Full Year Financial and Operating Results Achieves record quarterly reproductive health revenues and test volume, across-the-board increases in average revenue per test, expanded gross margin, significantly narrowed operating loss and record cash collections Affirms outlook to reach positive cash flow from operations by the fourth quarter of 2017 Conference call begins today at 4:30 p.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2017 CombiMatrix Corporation (Exact name of registrant as specified in its charter) Delaware 001-33523 47-0899439 (State or other jurisdiction) (Commission (I.
Exhibit 10.1 COMBIMATRIX CORPORATION 2017 EXECUTIVE PERFORMANCE BONUS PLAN Purpose Pursuant to the authority granted under CombiMatrix Corporation Compensation Committee Charter, the Compensation Committee (the “Committee”) of CombiMatrix Corporation (the “Company” or “our”) has adopted this 2017 Executive Performance Bonus Plan (the “Plan”) effective as of January 1, 2017. The purpose of this Plan is to motivate executives to achieve the Company’s objectives and to minimize turnover f
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2017 CombiMatrix Corporation (Exact name of registrant as specified in its charter) Delaware 001-33523 47-0899439 (State or other jurisdiction of incorporation) (Commission File Number) (I.
2018-05-19 - Asif
OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...
2018-05-19 - Asif
Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...
2018-05-17 - Asif
Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...
as of ET